BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37224918)

  • 1. APOL1 channel blocker reduces proteinuria in FSGS.
    Olabisi OA
    Kidney Int; 2023 Aug; 104(2):228-230. PubMed ID: 37224918
    [No Abstract]   [Full Text] [Related]  

  • 2. APOL1 genotype-associated morphologic changes among patients with focal segmental glomerulosclerosis.
    Zee J; McNulty MT; Hodgin JB; Zhdanova O; Hingorani S; Jefferson JA; Gibson KL; Trachtman H; Fornoni A; Dell KM; Reich HN; Bagnasco S; Greenbaum LA; Lafayette RA; Gipson DS; Brown E; Kretzler M; Appel G; Sambandam KK; Tuttle KR; Chen D; Atkinson MA; Hogan MC; Kaskel FJ; Meyers KE; O'Toole J; Srivastava T; Sethna CB; Hladunewich MA; Lin JJ; Nast CC; Derebail VK; Patel J; Vento S; Holzman LB; Athavale AM; Adler SG; Lemley KV; Lieske JC; Hogan JJ; Gadegbeku CA; Fervenza FC; Wang CS; Matar RB; Singer P; Kopp JB; Barisoni L; Sampson MG
    Pediatr Nephrol; 2021 Sep; 36(9):2747-2757. PubMed ID: 33646395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. APOL1 risk genotype in European steroid-resistant nephrotic syndrome and/or focal segmental glomerulosclerosis patients of different African ancestries.
    Gribouval O; Boyer O; Knebelmann B; Karras A; Dantal J; Fourrage C; Alibeu O; Hogan J; Dossier C; Tête MJ; Antignac C; Servais A
    Nephrol Dial Transplant; 2019 Nov; 34(11):1885-1893. PubMed ID: 29992269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. APOL1 in an ethnically diverse pediatric population with nephrotic syndrome: implications in focal segmental glomerulosclerosis and other diagnoses.
    Watanabe A; Guaragna MS; Belangero VMS; Casimiro FMS; Pesquero JB; de Santis Feltran L; Palma LMP; Varela P; de Menezes Neves PDM; Lerario AM; de Souza ML; de Mello MP; de Brito Lutaif ACG; Ferrari CR; Sampson MG; Onuchic LF; Nogueira PCK
    Pediatr Nephrol; 2021 Aug; 36(8):2327-2336. PubMed ID: 33585978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in molecular diagnosis and therapeutics in nephrotic syndrome and focal and segmental glomerulosclerosis.
    Sharif B; Barua M
    Curr Opin Nephrol Hypertens; 2018 May; 27(3):194-200. PubMed ID: 29465426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does copy number variation of APOL1 gene affect the susceptibility to focal segmental glomerulosclerosis?
    Peng T; Li G; Zhong X; Wang L
    Ren Fail; 2017 Nov; 39(1):500-504. PubMed ID: 28494221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The treatment of idiopathic focal segmental glomerulosclerosis in adults.
    Hogan J; Radhakrishnan J
    Adv Chronic Kidney Dis; 2014 Sep; 21(5):434-41. PubMed ID: 25168833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inaxaplin for Proteinuric Kidney Disease in Persons with Two
    Egbuna O; Zimmerman B; Manos G; Fortier A; Chirieac MC; Dakin LA; Friedman DJ; Bramham K; Campbell K; Knebelmann B; Barisoni L; Falk RJ; Gipson DS; Lipkowitz MS; Ojo A; Bunnage ME; Pollak MR; Altshuler D; Chertow GM;
    N Engl J Med; 2023 Mar; 388(11):969-979. PubMed ID: 36920755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucocorticoids Induce Partial Remission of Focal Segmental Glomerulosclerosis but Not Interstitial Nephritis in COVID-19 Acute Kidney Injury in an APOL1 Low-Risk Genotype White Patient.
    Nowak PJ; Forycka J; Cegielska N; Harendarz K; Wągrowska-Danilewicz M; Danilewicz M; Płoszaj T; Borowiec M; Wlazeł R; Nowicki M
    Am J Case Rep; 2021 Nov; 22():e933462. PubMed ID: 34727096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. APOL1 risk variants affect podocyte lipid homeostasis and energy production in focal segmental glomerulosclerosis.
    Ge M; Molina J; Ducasa GM; Mallela SK; Varona Santos J; Mitrofanova A; Kim JJ; Liu X; Sloan A; Mendez AJ; Banerjee S; Liu S; Szeto HH; Shin MK; Hoek M; Kopp JB; Fontanesi F; Merscher S; Fornoni A
    Hum Mol Genet; 2021 Apr; 30(3-4):182-197. PubMed ID: 33517446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Novel Genetic Risk Factors for Focal Segmental Glomerulosclerosis in Children: Results From the Chronic Kidney Disease in Children (CKiD) Cohort.
    Durand A; Winkler CA; Vince N; Douillard V; Geffard E; Binns-Roemer E; Ng DK; Gourraud PA; Reidy K; Warady B; Furth S; Kopp JB; Kaskel FJ; Limou S
    Am J Kidney Dis; 2023 Jun; 81(6):635-646.e1. PubMed ID: 36623684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing Kidney Health Outcomes in Children, Adolescents, and Adults With Focal Segmental Glomerulosclerosis.
    Gipson DS; Troost JP; Spino C; Attalla S; Tarnoff J; Massengill S; Lafayette R; Vega-Warner V; Adler S; Gipson P; Elliott M; Kaskel F; Fermin D; Moxey-Mims M; Fine RN; Brown EJ; Reidy K; Tuttle K; Gibson K; Lemley KV; Greenbaum LA; Atkinson MA; Hingorani S; Srivastava T; Sethna CB; Meyers K; Tran C; Dell KM; Wang CS; Yee JL; Sampson MG; Gbadegesin R; Lin JJ; Brady T; Rheault M; Trachtman H
    JAMA Netw Open; 2022 Aug; 5(8):e2228701. PubMed ID: 36006643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early recurrence of focal segmental glomerulosclerosis in a kidney transplant recipient with
    Acharya R; Upadhyay K
    BMJ Case Rep; 2023 May; 16(5):. PubMed ID: 37258049
    [No Abstract]   [Full Text] [Related]  

  • 14. A glomerular transcriptomic landscape of apolipoprotein L1 in Black patients with focal segmental glomerulosclerosis.
    McNulty MT; Fermin D; Eichinger F; Jang D; Kretzler M; Burtt NP; Pollak MR; Flannick J; Weins A; Friedman DJ; ; Sampson MG
    Kidney Int; 2022 Jul; 102(1):136-148. PubMed ID: 34929253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent Advances in Treatments of Primary Focal Segmental Glomerulosclerosis in Children.
    Han KH; Kim SH
    Biomed Res Int; 2016; 2016():3053706. PubMed ID: 27195285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meclofenamate treatment of recurrent idiopathic nephrotic syndrome with focal segmental glomerulosclerosis after renal transplantation.
    Torres VE; Velosa JA; Holley KE; Frohnert PP; Zincke H; Sterioff S
    Mayo Clin Proc; 1984 Mar; 59(3):146-52. PubMed ID: 6369011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association of low birthweight and prematurity on outcomes in children and adults with nephrotic syndrome-a NEPTUNE cohort study.
    Hingorani S; Gibson KL; Xie Y; Wang Y; Eddy S; Hartman J; Sampson M; Cassol C; Thomas D; Gipson DS; Trachtman H; Srivastava T; Reidy K;
    Pediatr Nephrol; 2023 Oct; 38(10):3297-3308. PubMed ID: 37140708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. APOL1-associated glomerular disease among African-American children: a collaboration of the Chronic Kidney Disease in Children (CKiD) and Nephrotic Syndrome Study Network (NEPTUNE) cohorts.
    Ng DK; Robertson CC; Woroniecki RP; Limou S; Gillies CE; Reidy KJ; Winkler CA; Hingorani S; Gibson KL; Hjorten R; Sethna CB; Kopp JB; Moxey-Mims M; Furth SL; Warady BA; Kretzler M; Sedor JR; Kaskel FJ; Sampson MG
    Nephrol Dial Transplant; 2017 Jun; 32(6):983-990. PubMed ID: 27190333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-Dose Rituximab Ineffective for Focal Segmental Glomerulosclerosis: A Long-Term Observation Study.
    Roccatello D; Sciascia S; Rossi D; Alpa M; Naretto C; Radin M; Barreca A; Fenoglio R; Baldovino S; Menegatti E
    Am J Nephrol; 2017; 46(2):108-113. PubMed ID: 28700988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Podocyte-Targeted Treatment for Proteinuric Kidney Disease.
    Mundel P
    Semin Nephrol; 2016 Nov; 36(6):459-462. PubMed ID: 27987545
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.